Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:8 Issue:3 Number:10 ISSN#:2564-2537
Author Verified
RCT
ACE Report #10871
Ace Report Cover Cannabis

Titrated THC:CBD Improves Pain and Spasticity Compared to Placebo Over 12 Weeks for Resistant MS


How to Cite

OrthoEvidence. Titrated THC:CBD Improves Pain and Spasticity Compared to Placebo Over 12 Weeks for Resistant MS. ACE Report. 2019;8(3):10. Available from: https://myorthoevidence.com/AceReport/Report/10871

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Sativex as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial

Int J Neurosci. 2018 Sep 13:1-10.

Contributing Authors: M Marinelli C Vila JE Markova B Akmaz C Trompke A Lentschat U Essner

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

106 patients with resistant multiple sclerosis who had demonstrated adequate treatment response to Sativex (tetrahydrocannabinol and cannabidiol oromucosal spray) treatment in a 4-week trial phase were randomized to Sativex or placebo for 12 weeks after 1-4 week washout from the trial phase. The purpose of the study was to determine if tetrahydrocannabinol and cannabidiol oromucosal spray (THC:CBD...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE
For Reprints and Permissions, click here

Please Login or Join to leave comments.